HIGHLIGHTS   |  November 23, 2019   FDA Approves Acalabrutinib to Treat CLL/SLL As part of Project Orbis, The FDA has approved acalabrutinib (Calquence) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Read more     FDA Accepts Biologics License Application for Bevacizumab Biosimilar The FDA has accepted a biologics license application (BLA) under the 351(k) pathway for SB8, a biosimilar candidate for bevacizumab (Avastin), according to Samsung Bioepis, the developer of the agent. Read more IN CASE YOU MISSED IT   Patient-Reported Outcomes Bolster Breast Cancer Treatment Survival of patients with metastatic breast cancer has improved substantially over recent decades, but a new study shows that there is substantial regional variation in survival and in the improvement in survival. Read more